IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Area of Science:

• Neuroscience
• Genetics
• Clinical Trials

Background:

• Autosomal dominant cerebellar ataxia (ADCA) is a group of debilitating neurodegenerative disorders.
• Current treatment options for ADCA are limited, necessitating the exploration of novel therapeutic strategies.
• Insulin-like Growth Factor 1 (IGF-1) has emerged as a potential therapeutic agent for neurodegenerative conditions.

Purpose of the Study:

• To evaluate the safety, tolerability, and efficacy of IGF-1 therapy in patients with ADCA.
• To assess the impact of IGF-1 on the progression of spinocerebellar ataxias (SCA), specifically SCA3, SCA6, and SCA7.

Main Methods:

• An open-label clinical trial involving 26 patients with genetically confirmed ADCA (19 SCA3, 1 SCA6, 6 SCA7).
• Patients received IGF-1 therapy at a dosage of 50 μg/kg twice daily for 12 months.
• Efficacy was measured by changes in the Scale for the Assessment and Rating of Ataxia (SARA) scores from baseline.

Main Results:

• IGF-1 therapy was found to be safe and well-tolerated in the study population.
• A statistically significant improvement in SARA scores was observed in patients with SCA3, SCA7, and overall after one year of treatment.
• Disease stabilization was noted during a second year of open-label extension, suggesting sustained therapeutic effects.

Conclusions:

• IGF-1 therapy demonstrates a trend towards stabilizing disease progression in patients with spinocerebellar ataxias (SCA).
• These findings suggest that IGF-1 may be a viable therapeutic option for decreasing the progressivity of ADCA.
• Further research and larger trials are warranted to confirm these promising results.